A Study of LY3471851 in Healthy Participants

Nektar Therapeutics36 enrolled

Overview

The main purpose of this study is to explore the safety and tolerability of LY3471851 in healthy Japanese and Caucasian participants. The study will also estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it. The study is expected to last about 7 weeks for each participant.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Enrollment

Conditions

Healthy

Interventions

LY3471851DRUG

Administered SC

PlaceboDRUG

Administered SC

Eligibility

Sex: ALLMin age: 20 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Are healthy males or females, as determined by medical history and physical examination * Are first generation Japanese or are Caucasian * Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive, at the time of screening Exclusion Criteria: * Are currently enrolled in a clinical study involving an investigational product (IP) or any other type of medical research judged not to be scientifically or medically compatible with this study * Have an abnormal blood pressure and/or pulse rate as determined by the investigator * Regularly use known drugs of abuse and/or show positive findings on drug screening * Are immunocompromised per investigator judgment

Locations (1)

WCCT Global

Cypress, California, United States

Outcomes

Primary Outcomes

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module

Time frame: Baseline through Study Completion (up to week 7)

Secondary Outcomes

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3471851

PK: AUC of LY3471851

Time frame: Predose on Day 1 through Day 50

PK: Maximum Concentration (Cmax) of LY3471851

PK: Cmax of LY3471851

Time frame: Predose on Day 1 through Day 50

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.